Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.

Ashi, Mohamad Omar et al.·Exploration of targeted anti-tumor therapy·2022·
RPEP-059892022RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Not classified
Evidence
Not graded
Sample
Not reported

What This Study Found

TEIPP derived from non-mutant proteins may effectively target immune-edited tumors.

Key Numbers

How They Did This

The study is a review of existing literature on cancer vaccines and immune checkpoint therapies.

Why This Research Matters

Understanding how to effectively target resistant tumors could lead to better cancer treatments. This research may help improve outcomes for patients who currently do not respond to existing therapies.

What This Study Doesn't Tell Us

As a review, it does not present new experimental data and relies on existing studies, which may vary in quality.

Trust & Context

Original Title:
Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.
Published In:
Exploration of targeted anti-tumor therapy, 3(6), 746-762 (2022)
Database ID:
RPEP-05989

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Read More on RethinkPeptides

Related articles coming soon.

Cite This Study

RPEP-05989·https://rethinkpeptides.com/research/RPEP-05989

APA

Ashi, Mohamad Omar; Mami-Chouaib, Fathia; Corgnac, Stéphanie. (2022). Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.. Exploration of targeted anti-tumor therapy, 3(6), 746-762. https://doi.org/10.37349/etat.2022.00111

MLA

Ashi, Mohamad Omar, et al. "Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises.." Exploration of targeted anti-tumor therapy, 2022. https://doi.org/10.37349/etat.2022.00111

RethinkPeptides

RethinkPeptides Research Database. "Mutant and non-mutant neoantigen-based cancer vaccines: rece..." RPEP-05989. Retrieved from https://rethinkpeptides.com/research/ashi-2022-mutant-and-nonmutant-neoantigenbased

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.